B. Riley FBR to Host NASH Symposium in San Francisco on October 24, 2019
Biotech Investor Event to Explore Latest NASH Developments and Controversies in Facilitated Company Discussions
LOS ANGELES, Oct. 21, 2019 /PRNewswire/ -- B. Riley FBR, Inc., a full-service investment bank and a B. Riley Financial company (NASDAQ: RILY) ("B. Riley"), today announced it will host a biotech investor event to discuss emerging trends in non-alcoholic steatohepatitis (NASH) on Thursday, October 24, 2019, in San Francisco. This invitation-only NASH Symposium will gather institutional investors and senior management teams across the healthcare industry to discuss the latest developments and treatments for non-alcoholic fatty liver disease (NAFLD)—one of the most common liver diseases in the world.
NASH industry experts will have an opportunity to delve into the controversies related to scientific mechanisms, preclinical and clinical development programs, regulatory endpoints, and the market potential of emerging treatment options for "true" NASH non-cirrhotic and cirrhotic patients.
"Biopharma industry investments in NASH have significantly increased over the last three years given the enormous burden to the healthcare system, the volume of affected patients, and the chronic nature of the disease," said Mayank Mamtani, Senior Biotech Research Analyst, B. Riley FBR. "NAFLD is expected to become the leading cause of liver transplantation by 2020, with approximately 60-80 million people, or 20-25 percent of the U.S. adult population impacted. There is currently no FDA-approved treatment option for this costly, broad spectrum disease."
The NASH Symposium will feature facilitated company and investor discussions with key opinion leader, Dr. Stephen Harrison, an internationally known expert in hepatitis C and NAFLD. Company participants currently include:
- Altimmune (ALT)
- Cirius Pharmaceuticals (private)
- Durect Corporation (DRRX)
- Genfit SA (GNFT)
- Gilead Sciences (GILD)
- INmune Bio (INMB)
- Lipocine (LPCN)
- NGM Biopharmaceuticals (NGM)
- Sagimet Biosciences (private)
- Terns Pharmaceuticals (private)
The event is by invitation only. Interested participants may contact their B. Riley FBR representative for more information. A complete schedule will be provided upon registration.
About B. Riley FBR, Inc.
B. Riley FBR is a full-service investment bank and subsidiary of B. Riley Financial, which provides corporate finance, research and sales and trading to corporate, institutional and high-net-worth individual clients. Investment banking services include initial, secondary and follow-on offerings, institutional private placements, merger and acquisitions advisory services, and corporate restructuring. The firm is nationally recognized for its highly ranked proprietary equity research. For more information, visit www.brileyfbr.com.
About B. Riley Financial, Inc. (NASDAQ:RILY)
B. Riley Financial provides collaborative financial services tailored to fit the capital raising and business advisory needs of public and private companies and high-net-worth individuals. B. Riley operates through several wholly-owned subsidiaries which offer complementary end-to-end capabilities spanning investment banking and institutional brokerage, private wealth and investment management, corporate advisory, restructuring, due diligence, forensic accounting and litigation support, appraisal and valuation, and auction and liquidation services. Certain registered affiliates of B. Riley originate and underwrite senior secured loans for asset-rich companies. The Company also makes proprietary investments in companies and assets with attractive return profiles. For more information, visit www.brileyfin.com.
Media Contact
Jo Anne McCusker
B. Riley Financial
[email protected]
(646) 885-5425
SOURCE B. Riley FBR, a B. Riley Financial company
Related Links
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article